Merck related Press Releases
Merck Statement in Response to FDA's June Communication with Updated Information on Leukotriene Inhibitors, Including Singulair
Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium)
WHITEHOUSE STATION,... Read more...
Neuromed Pharmaceuticals Announces that Merck Terminates Research Collaboration and License Agreement
Neuromed Pharmaceuticals Announces that Merck Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels CONSHOHOCKEN, PA and VANCOUVER, BC, June 11... Read more...
Xenon Enters Cardiovascular Disease Collaboration With Merck & Co., Inc.
Xenon Enters Cardiovascular Disease Collaboration With Merck & Co., Inc. VANCOUVER, Canada, June 11 /PRNewswire/ -- Xenon today announced a strategic alliance with Merck & Co., Inc.,... Read more...
Merck to Launch TREDAPTIVETM (ER niacin/laropiprant) in International Markets Later This Year
Merck to Launch TREDAPTIVETM (ER niacin/laropiprant) in International Markets Later This Year WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. will begin launching TREDAPTIVETM (ER... Read more...
Studies of GARDASIL, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at Conference
Studies of GARDASIL, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference
Data from an Extension of a Phase II Study
... Read more...Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM OXFORD, England, April 24 /PRNewswire/ -- PharmaVentures Ltd, announced today that it has been engaged
... Read more...Merck Announces Interim Phase IIa Study Results of MK-7009, an Investigational Oral Hepatitis C Virus Protease Inhibitor
Merck Announces Interim Phase IIa Study Results of MK-7009, an Investigational Oral Hepatitis C Virus Protease Inhibitor, in Patients with Chronic Hepatitis C
Phase IIb Trial will Further
... Read more...Merck & Co., Inc. and Santen Sign Licensing Agreement In Ophthalmology
Merck & Co., Inc. and Santen Sign Licensing Agreement In Ophthalmology WHITEHOUSE STATION, N.J. - (Business Wire) Merck & Co., Inc. and Santen Pharmaceutical Co., Ltd. today announced a
... Read more...Merck Provides Update on Merger Financing
Merck Provides Update on Merger Financing
WHITEHOUSE STATION, N.J., March 23, 2009 - Merck & Co., Inc. today provided an update on the status of credit facilities that will be used to
... Read more...Merck & Co., Inc. Provides Update on Previously-Disclosed U.S. Department of Justice Investigation Relating to VIOXX®
Merck & Co., Inc. Provides Update on Previously-Disclosed U.S. Department of Justice Investigation Relating to VIOXX®
WHITEHOUSE STATION, N.J., March 23, 2009 - Merck & Co., Inc.
... Read more...Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
